Combination immunotherapy produces high response rate in early results of Sylvester trial targeting high-risk follicular lymphoma
DOWNOADABLE VIDEO
MIAMI, FLORIDA (EMBARGOED UNTIL MONDAY, DEC. 11, 2023 AT 8:45 P.M. ET) – Researchers conducting a Phase 2 clinical trial at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine say a new combination of antibody therapies produced a ‘surprisingly high’ response rate in patients with high-risk follicular lymphoma, a type of non-Hodgkin lymphoma.
Based on these initial findings – reported in an oral presentation at the 65th ASH Annual Meeting and Exposition in San Diego, California, Dec. 9-12 – the research team plans to expand the number of trial participants ...











